Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.

Frontiers in immunology - 1 Jan 2020

Ding Xing-Chen, Wang Liang-Liang, Zhu Yu-Fang, Li Yan-Dong, Nie Shu-Lun, Yang Jia, Liang Hua, Weichselbaum Ralph R, Yu Jin-Ming, Hu Man

Abstract excerpt

Background: The programmed cell death ligand 1 (PD-L1) plays a key role in glioma development. However, due to the specificity of glioma's anatomical position, the role of its expression as a tumor biomarker is limited. It has been proven that the levels of soluble programmed death-ligand 1 (sPD-L1) are associated with prognosis in many malignancies including glioma. However, the expression of sPD-L1 in glioma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Gene Expression Regulation, Neoplastic

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Survival Analysis

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 33224142
DOI: 10.3389/fimmu.2020.580335
PMCID: PMC7668030

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.PMID 33224142Read ↗

The Change of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical OutcomeSemantic proximity Read ↗

Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade gliomaSemantic proximity Read ↗

Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomasSemantic proximity Read ↗

Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain gliomaSemantic proximity Read ↗

PD-L1-related LncRNAs are Associated with Immune Microenvironment and Prognosis in GliomaSemantic proximity Read ↗

Comprehensive analysis of PD-L1 expression in glioblastoma multiforme.Semantic proximity Read ↗

Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.Semantic proximity Read ↗

Programmed Death Ligand-1 Expression in Gliomas: A Study of Histopathological and Molecular Associations.Semantic proximity Read ↗

[Level of soluble programmed death-1 ligand 1 in peripheral blood of patients with advanced epidermal growth factor receptor mutated lung adenocarcinoma and its clinical implications].Semantic proximity Read ↗

A radiosensitivity gene signature and PD-L1 predict the clinical outcomes of patients with lower grade glioma in TCGA.Semantic proximity Read ↗

Characterization of clinical significance of PD-1/PD-Ls expression and methylation in patients with low grade gliomaSemantic proximity Read ↗

Association of PD-1.5 C/T, but Not PD-1.3 G/A, with Malignant and Benign Brain Tumors in Iranian Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.